NEWLY APPROVED HEAD AND NECK CANCER TREATMENT IMPROVES CARE FOR FIRST TIME IN MORE THAN 20 YEARS

The National Institute for Health and Care Excellence (NICE) has recommended an immunotherapy to treat advanced head and neck cancer for use on the NHS in England. In final draft guidance, published on 24 March 2026, NICE approved pembrolizumab (Keytruda; MSD), an IV infusion for patients with resectable locally advanced head and neck squamous cell […]